AIP · Arteris, Inc.

The thesis

Arteris is still growing, but the shares have not recovered from the autumn decline, and the third-quarter report decides whether the August guidance holds. The adjusted close on 27 October 2026 was $20.95, 56.9% below the 52-week high of $48.59, and the three-month price change was negative 28.5%. The close on 14 October 2026 was $19.67, so the shares have rebounded slightly from the low of the move, and they remain well under the prior highs.

Arteris licenses the design blocks that carry data between the parts of a chip. Revenue rose 46% to $24.13 million in the second quarter, reported 6 August 2026, and full-year revenue guidance was raised to $95–98 million. Third-quarter guidance is revenue of $24–25 million.

The narrative is maturing: the story is well known, the August results confirmed the growth, and the shares have fallen since that report. The 14-day Relative Strength Index (RSI), a momentum gauge where readings under 30 are called oversold, stood at 38.9 on 27 October 2026, up from 21.5 on 14 October 2026. The company announced the date of its third-quarter report on 22 October 2026. Earnings Whispers lists 5 November 2026 after the close.

The rating stays at the lower tier. Since the prior note there has been a release-date announcement and a TD Cowen target cut, and no new financial result. The shares are more likely to track the print than the index until the report is out.

Bullish and bearish views on Arteris, Inc.

The bull case on Arteris, Inc. (AIP), in brief: Revenue and guidance both moved up. The bear case: The decline is deep.

Bull case

• Revenue and guidance both moved up. Arteris reported second-quarter 2026 revenue of $24.13 million, up 46% year over year, on 6 August 2026 and raised the full-year range to $95–98 million. Third-quarter guidance is revenue of $24–25 million and a non-GAAP operating loss of $1–3 million.
• Royalties follow design wins by roughly 18–24 months, so the line reflects earlier bookings.
• Chiplets widen the market. Craig-Hallum initiated coverage on 21 September 2026 with a Buy rating and a $30 target, saying chiplets are about 10% of chip designs and could reach 30% or more. Arteris introduced FlexGen Multi-Die on 15 September 2026 to early-access partners and disclosed no revenue from it.
• Analyst targets sit far above the price. MarketBeat on 29 September 2026 listed seven analysts at Moderate Buy with an average target of $39.43. Jefferies' target is $50 and Rosenblatt's is $38.
• Customer and security news continues. Arteris announced an expanded third-party IP security assurance program with BAE Systems and SiFive on 6 October 2026, with no financial terms. A company-news item dated 27 October 2026 reports Tenstorrent expanding its deployment of Arteris network-on-chip IP; no contract value has been disclosed.

Bear case

• The decline is deep. The close fell from $24.01 on 1 October 2026 to $19.67 on 14 October 2026 and stood at $20.95 on 27 October 2026. Both moving averages MarketBeat reported on 29 September 2026, $25.58 (50-day) and $28.30 (200-day), sit well above that close.
• Analysts are trimming targets. Company news dated 19 October 2026 reports TD Cowen lowered its price target on Arteris. InsiderTrades reported TD Cowen had raised its target to $40 from $22 on 13 May 2026.
• Insiders have been selling. MarketBeat on 29 September 2026 listed insider sales of 1,177,382 shares worth about $37.7 million over 90 days, including 100,000 shares by Bayview Legacy, LLC on 1 September 2026.
• Growth still carries losses. The second-quarter GAAP net loss was $0.30 per share against a $0.10 non-GAAP loss. Management guided to a full-year adjusted operating loss of $7–10 million.
• A new finance chief sets his first guidance. Saurabh Sinha became Chief Financial Officer on 8 September 2026 after Nicholas Hawkins retired, and the third-quarter report is the first guide under him.

Price setup

The adjusted close of $20.95 on 27 October 2026 sits above the $19.56 April 2026 low, which the October decline approached without a recorded close below it. That level is the line the invalidation condition uses.

The shares trade under both moving averages MarketBeat reported on 29 September 2026: $25.58 (50-day) and $28.30 (200-day). The moving averages have since moved lower with the price. The 52-week high of $48.59 sits 56.9% above the current close.

Crowding evidence points to supply rather than demand. MarketBeat's 90-day insider tally of 1,177,382 shares sold is the largest observable flow. An earnings date within about ten days adds event risk, and MarketBeat lists a beta of 1.91.

Catalysts, next 30 days

• Same report — first guidance cycle under Chief Financial Officer Saurabh Sinha. The fourth-quarter and full-year outlook show whether the August raise survives.

Elapsed catalysts

• ~5 November 2026, est. third-quarter 2026 results. The company announced the release date on 22 October 2026; Earnings Whispers lists 5 November 2026 after the close. The report tests the $24–25 million revenue guide, the $95–98 million full-year range and royalty growth against the 65% reported in Q2. (passed 1d ago)

What would change the view

The case breaks if third-quarter revenue comes in under the $24 million guidance floor, or if the $95–98 million full-year range is cut. A non-GAAP operating loss above $3 million would also show losses widening against guidance. Slower trailing-twelve-month royalty growth than the 65% reported in Q2 would weaken the lead operating measure.

On price, a weekly close below $19.56, the April 2026 low, would end the repair case. A report that meets guidance and raises the full-year range, with royalties growing near the Q2 pace, would argue for a higher rating; the share-price move alone would not.

What it trades with

Arteris sells design intellectual property into chip makers, so its orders follow semiconductor design starts, with revenue from royalties lagging by roughly 18–24 months. The shares carry a beta of 1.91 per MarketBeat, so moves in AI-chip and small-cap technology shares tend to be amplified. No commodity or materials exposure applies. Customer and partner announcements such as Tenstorrent, BAE Systems and SiFive have not carried disclosed revenue figures, so they move sentiment before they move reported numbers.